


# Antidepressants

- often life-saving drugs


## A possible classification of antidepressants

1. Non-selective monoamines reuptake inhibitors (tricyclic and tetracyclic antidepressants)
2. Monoaminooxidases (MAO) inhibitors
  - 2.1 Non-selective MAO inhibitors
  - 2.2 Selective MAO A inhibitors
3. Selective serotonin and noradrenaline reuptake inhibitors (SSNRI)
4. Selective serotonin reuptake inhibitors (SSRI)
5. Dual-serotonergic antidepressants
6. Selective noradrenaline reuptake inhibitors (SNRI)
7. Selective noradrenaline and dopamine reuptake inhibitors
8. Melatonergic agonists
9. “Other” tricyclic antidepressants
10. Alkaline metals salts


## Amines mainly involved in effects of antidepressants



4-[(1*R*)-2-amino-1-hydroxyethyl]benzene-1,2-diol  
**noradrenaline** (norepinephrine)



4-(2-aminoethyl)benzene-1,2-diol  
**dopamine**





3-(2-aminoethyl)-1*H*-indol-5-ol  
**serotonin**

# 1. Non-selective monoamines reuptake inhibitors (tricyclic antidepressants)

- inhibit reuptake of serotonin and noradrenaline

## Genesis (derivation) of tricyclic antidepressants







**Fig. 1.5** The tricyclic antidepressants (imipramine and maprotiline) are characterized by a dihedral angle of  $55^\circ$  to  $65^\circ$  between the two benzo rings; this angle is only  $25^\circ$  for the tricyclic neuroleptics (chlorpromazine, chlorprothixene) [12].

1<sup>st</sup> and 2<sup>nd</sup> generations of tricyclic antidepressants

- act inhibitory also on M, H<sub>1</sub>, α<sub>1</sub>, α<sub>2</sub>, 5-HT<sub>2</sub> receptors
- 2<sup>nd</sup> gen. increases more amount of NA than 5-HT in synapsis, 1<sup>st</sup> gen. reversely



R<sup>1</sup>=-CH<sub>3</sub> R<sup>2</sup>=R<sup>3</sup>=-H

Tofranil®

R<sup>1</sup>= R<sup>2</sup>=R<sup>3</sup>=-H

R<sup>1</sup>= R<sup>2</sup>=-H R<sup>3</sup>=-Cl

Anafranil®

R<sup>1</sup>= R<sup>2</sup>=-CH<sub>3</sub> R<sup>3</sup>=-H

Surmontil®

**imipramine**

**desipramine**

**clomipramine**

**trimipramine**


R<sup>1</sup>=-CH<sub>3</sub> **amitriptyline**

Elavil®, Endep®


R<sup>1</sup>=-H **nortriptyline**

**Pamelor®**

## 1<sup>st</sup> generation of tricyclic antidepressants



**cidoxepin [INN]**  
syn. doxepin [USAN]



**dosulepin [INN]**  
syn. dothiepin [USAN]  
Prothiaden ® 25


## Mechanism of action:

- Inhibition of neurotransmitters reuptake
- Immediate effect =  $>\uparrow$  NA and 5-HT in synapsis.
- After longer period treatment (2 - 4 weeks) =  $>$ 
  - $\downarrow$  of activity  $\beta$  and  $\downarrow$ 5-HT<sub>2</sub> rp.
  - $\downarrow$  of release and return of NA
  - $\downarrow$  NA-stimulated cAMP level in the brain
  - $\uparrow$  sensitivity of 5-HT receptors
  - \* „Adaptive responses“ \*
- as long as 4 weeks of treatment are needed for full activity

Unwanted effects of tricyclic antidepressants due to antagonist action on various receptors:


- M(uscarine) rp. - dry in the mouth, bad accommodation, tachycardia, problems with emiction, forgetting
- H<sub>1</sub> rp. - sedation, increase of body weight
- 5-HT<sub>2</sub> - increase of appetite and body weight
- $\alpha_1$  - orthostatic hypotension, reflex tachycardia

## Tetracyclic antidepressants (or „thymoleptics of 2<sup>nd</sup> generation“)




**mianserin**

- minimal activity on monoamines reuptake from synapses, quite selective antagonists of  $\alpha_2$ -adrenergic receptors which inhibit noradrenaline release



**mirtazapine**

Esprital ® , Mirtazapin ® *firm*



**maprotiline**

inhibits reuptake of noradrenaline mainly

- moderate anticholinergic effects, significant antihistamine ones (sedative)

Ludiomil ®


• inhibits also  $\alpha_1$ -rp.  $\Rightarrow$   
 $\downarrow$  blood pressure  
Lerivon ® , Miabene ®




## 2. Monoaminooxidases (MAO) inhibitors – also thymoeretics

- MAOs = enzymes oxidatively degrading catecholamines
- discovered in 1950<sup>th</sup>
- potent but less used due to their lower security (interactions, unwanted effects)
- frequent occurrence of drug interactions
- most frequently used if other treatment methods failed
- AE: orthosthesis, sedation, sexual dysfunctions, body weight increase
  
- type A (MAO-A) decomposes mainly serotonin and less also noradrenaline
- typ B (MAO-B) decomposes various phenylethylamine including dopamine


## 2.1 Non-selective MAO inhibitors




isonicotinic acid N'-  
isopropylhydrazide  
**iproniazid**



1-(2-phenylethyl)hydrazine  
**phenelzine**




4-methylisoxazole-3-  
karboxylic acid N'-  
benzylhydrazide  
**isocarboxazid**



*trans*-2-  
phenylcyclopylamin  
**transylcypromine**


•dangerous interaction with „exciting amines“ in food (maturing cheeses, red wines) especially tyramine  $\Rightarrow$   $\uparrow$  blood pressure to hypertension crisis




tyramine

## 2.2 Selective MAO A inhibitors


- MAO A decomposes mainly endogenous noradrenaline (NA) and serotonin (5HT)



**moclobemide**  
N-(2-morpholinoethyl)-4-chlorobenzamide  
Aurorix®




**tolloxatone**



**amiflamine**

### 3. Serotonin and noradrenaline reuptake inhibitors (SNRI)


·indirect central agonists of both adrenergic and 5HT receptors



1-[2-(dimethylamino)-1-(4-methoxyphenyl)  
ethyl]cyclohexanol

**venlafaxine**

Argofan ® , Apo-Venlafaxin ® , Velaxin ® ...




(3S)-1-methylamino-3-(1-naphtyloxy)-3-  
(thiophene-2-yl)propane


**duloxetine**

Cymbalta ® , Xeristar ®


#### 4. Selective serotonin reuptake inhibitors (SSRI)



**citalopram**  
Citalex®




**escitalopram**  
(S)-citalopram  
Depresinal ® , Elicea ®



3-(4-(trifluoromethyl)phenoxy)-3-phenyl-  
1-methylaminopropane

**fluoxetine**

Deprex<sup>®</sup>, Floxet<sup>®</sup>, Fluocim<sup>®</sup>,  
Fluval<sup>®</sup> ...




(1S,4S)-4-(3,4-dichlorophenyl)-1-methylamino-  
1,2,3,4-tetrahydronaphthalene

**sertraline**


Asentra<sup>®</sup>, Serlift<sup>®</sup>, Setralax<sup>®</sup>, Zoloft<sup>®</sup> ...

- slightly activates, can disturb the sleep if administered in the evening, increase of tension and anxiety possible, long half time – no problems with an omission of a single dose



**paroxetine**

Arketis ® , Parolex ®




**fluvoxamine**

- attenuating effects, administration in the evening, suitable for inquiet patients, inhibition of suicidal turns


Fevarin ®



## 5. Dual-serotonergic antidepressants



**trazodone**



**nefazodone**


- serotonine reuptake inhibitors and simultaneously 5-HT<sub>2</sub> receptor antagonists

- markedly sedative


Trittico AC ®

- also inhibits NA reuptake


## 6. Selective noradrenaline reuptake inhibitors (SNRI)



**reboxetine**  
•*R,R*




**viloxazine**  
•racemate



**atomoxetine**  
•*R*  
Strattera®

- effective in motivation and interest stimulation
- enhance effect of sympathomimetics
- AE : tachycardia, tremor

## 7. Selective noradrenaline and serotonin reuptake inhibitors




### **bupropion**

Elontril<sup>®</sup>, Welard<sup>®</sup>, Bupropion+Pharma<sup>®</sup> ...

•also treatment of nicotine abuse


## 8. Melatonergic agonists




### **agomelatine**

- MT<sub>1</sub> and MT<sub>2</sub> melatonin receptors agonist
- 5-HT<sub>2C</sub> receptor antagonist

Valdoxan<sup>®</sup>



## 9. „Other“ tricyclic antidepressants



**tianeptine**

Coaxil<sup>®</sup>, Atinepte<sup>®</sup>

- **in animals**
  - stimulates spontaneous activity of pyramide cells of hippocampus and accelerates their regeneration after functional inhibition
  - increases speed of serotonin reuptake by brain cortex and hippocampus neurons
- **in vitro**
  - no affinity to monoaminergic receptors and doesn't inhibit 5-HT, NA or dopamine absorption
  - may modulate synaptic glutamatergic transmission.
- **in humans:**
  - effect to symptoms related to depression
  - effect to mood disorders; classified to a central position between sedative and stimulating antidepressants
  - significant effect to somatic problems, mainly gastrointestinal ones linked with anxiety and mood disorders
  - no effect to
    - vigily
    - cholinergic system (no anticholinergic symptoms)

## 10. Alkaline metals salts

Li<sup>+</sup>

- mostly often  $\text{Li}_2\text{CO}_3$
- treatment of bipolar illness (formerly manio-depressive syndrome)
- high toxicity, low difference between therapeutic and toxic doses, plasmatic levels monitoring necessary

Rb<sup>+</sup>

- total amount in the body 400 – 900 mg
- potentiates noradrenergic and dopaminergic transmission of nervous impulses in CNS
- evidences of antidepressant effects